SOPHiA GENETICS SA provided preliminary earnings guidance for the full year ending December 31, 2023. Based on information currently available, for the full year ending December 31, 2023, the Company expects to report Fiscal Year results in line with guidance provided at Third Quarter earnings: Full-year reported revenue growth expected to be at or above 30%; 2023 operating losses to be below 2022 levels.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.03 USD | +1.62% | +1.41% | +6.79% |
Apr. 23 | Sophia Genetics Says Nigeria's Syndicate Bio Signs on to Implement Liquid Biopsy Offering | MT |
Apr. 23 | SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.79% | 328M | |
+8.05% | 3,020B | |
+5.58% | 82.93B | |
+3.69% | 76.85B | |
-14.62% | 53.04B | |
+31.16% | 50.15B | |
-24.56% | 46.71B | |
+17.75% | 41.41B | |
+55.21% | 36.1B | |
-10.24% | 24.64B |
- Stock Market
- Equities
- SOPH Stock
- News SOPHiA GENETICS SA
- SOPHiA GENETICS SA Provides Preliminary Earnings Guidance for the Full Year Ending December 31, 2023